Nano PharmaSolutions employs nanoformulation techniques to enhance the bioavailability of insoluble drugs, improving their delivery and absorption in the body. This technology addresses the issue of low solubility in pharmaceuticals, which limits therapeutic efficacy and negatively impacts patient outcomes.
Funding
$4.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many pharmaceutical drugs exhibit poor water solubility, leading to limited bioavailability and reduced therapeutic effectiveness. Traditional formulation techniques often rely on lipids, polymers, or solvents, which can introduce unwanted side effects or manufacturing complexities.
Solution
Nano PharmaSolutions addresses the challenge of poor drug solubility with its NanoTransformer® technology, a nanoformulation process that enhances the bioavailability of poorly soluble drugs without using lipids, polymers, or solvents. This approach improves drug delivery and absorption, potentially increasing therapeutic efficacy and improving patient outcomes. The NanoTransformer® platform is designed to be versatile, supporting drug formulation across all phases of development, and requires only small quantities of active pharmaceutical ingredient (API) for rapid development. Nano PharmaSolutions also offers GMP manufacturing services to support clinical and commercial production. Their Nano-CNS® platform specifically targets nose-to-brain delivery for central nervous system (CNS) drugs, offering a novel approach to treating neurological disorders.
Target Audience
The primary target audience includes pharmaceutical companies and drug developers seeking to improve the bioavailability and delivery of poorly soluble drug candidates, particularly those focused on central nervous system therapies.
Features
- NanoTransformer® technology for enhanced drug solubility and bioavailability
- Formulation process without lipids, polymers, or solvents
- Rapid development using small quantities of API
- GMP manufacturing capabilities for clinical and commercial production
- Nano-CNS® platform for nose-to-brain delivery of CNS drugs
- Streamlined formulation for all phases of drug development
- White papers available for download detailing the NanoTransformer® platform technology